Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) ROCE % : 29.56% (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Parnell Pharmaceuticals Holdings's annualized ROCE % for the quarter that ended in Dec. 2018 was 29.56%.

Parnell Pharmaceuticals Holdings ROCE % Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings ROCE % Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

ROCE %

Get a 7-Day Free Trial

-29.65

-29.50

-47.98

-47.01

29.56

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
ROCE %	Get a 7-Day Free Trial			-18.87	-29.50	-47.98	-47.01	29.56

Parnell Pharmaceuticals Holdings ROCE % Calculation

Parnell Pharmaceuticals Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	5.256	/	( ( (23.092 - 6.68)	+	(24.003 - 4.849) )	/ 2 )
	=	5.256	/	( (16.412	+	19.154)	/ 2 )
	=	5.256	/	17.783
	=	29.56 %

Parnell Pharmaceuticals Holdings's ROCE % of for the quarter that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2018 )		(Q: Dec. 2017 )		(Q: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2018 )		(Q: Dec. 2017 )		(Q: Dec. 2018 )
	=	5.256	/	( ( (23.092 - 6.68)	+	(24.003 - 4.849) )	/ 2 )
	=	5.256	/	( ( 16.412	+	19.154 )	/ 2 )
	=	5.256	/	17.783
	=	29.56 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2018) EBIT data.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Parnell Pharmaceuticals Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.